Abstracts tagged "tocilizumab and methotrexate (MTX)"

Abstract Number: 2377 • 2019 ACR/ARP Annual Meeting
Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry
Dimitrios Pappas¹, Taylor Blachley ², Steve Zlotnick ³, Jennie Best ³, Kelechi Emeanuru ² and Joel Kremer ⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Waltham, MA, ³Genentech, Inc., South San Francisco, CA, ⁴Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY
Background/Purpose: Methotrexate (MTX) is frequently prescribed with biologic disease-modifying antirheumatic drugs. Evidence has shown that tocilizumab (TCZ) monotherapy is effective in the treatment of patients…
Abstract Number: 2684 • 2019 ACR/ARP Annual Meeting
Real-world Comparative Study of Methotrexate vs Tocilizumab in Patients with Giant Cell Arteritis with Large Vessel Involvement
DIANA PRIETO- PENA¹, Mónica Calderón-Goercke ², Javier Loricera ³, Javier Narváez ⁴, Elena Aurrecoechea ⁵, Ignacio Villa ⁶, Santos Castañeda ⁷, Catalina Gómez-Arango ⁸, Antonio Mera ⁹, Eva Perez Pampín ⁹, Vicente Aldasoro Caceres ¹⁰, N Alvarez Rivas ¹¹, N Fernandez Llanio ¹², María Álvarez del buergo ¹³, Luisa Marena-Rojas ¹⁴, Francisca Sivera ¹⁵, Eva Galindez-Agirregoikoa ¹⁶, Roser Solans-Laqué ¹⁷, Susana Romero-Yuste ¹⁸, Lara Sanchez-Bilbao ¹⁹, Iñigo Gonzalez-Mazon ¹, Isabel Martínez Rodríguez ²⁰, Ignacio Banzo ²⁰, Miguel Angel González-Gay ²¹ and Ricardo Blanco ¹⁹, ¹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ²Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ³Rheumatology Department. Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, ⁵Rheumatology Department. Hospital Sierrallana, Torrelavega, Spain, ⁶Hospital de Sierrallana, Torrelavega, Cantabria, Spain, ⁷Rheumatology Department, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Spain, ⁸Hospital Alto Deba, Mondragon, Pais Vasco, Spain, ⁹Division of Rheumatology, Instituto de Investigación Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, Santiago de Compostela, Spain, ¹⁰Complejo Hospitalario de Navarra, Navarra, Navarra, Spain, ¹¹H. Lucus Augusti, Lugo, Spain, ¹²H. Arnau de Vilanova, Lerida, Spain, ¹³Hospital Río Carrión, Palencia, Castilla y Leon, Spain, ¹⁴Hospital La Mancha Centro, Alcázar de San Juan, Castilla-La Mancha, Spain, ¹⁵Hospital General Universitario de Elda, Elda, Spain, ¹⁶Hospital de Basurto, Bilbao, Pais Vasco, Spain, ¹⁷Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain., Barcelona, Catalonia, Spain, ¹⁸Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, ¹⁹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ²⁰Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²¹Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most common large vasculitis in elderly patients. According to previous studies, 50% of patients with GCA in whom…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].